Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CLPro inhibitors. (Q40068309)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28216367%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

title

Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CLPro inhibitors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28216367%20AND%20SRC:MED&resulttype=core&format=json

Middle East respiratory syndrome coronavirus

3 April 2020

main subject

0 references

Middle East

0 references

Middle East respiratory syndrome

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28216367%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Jiun-Jie Shie

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28216367%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

author name string

Jin Soo Shin

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28216367%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Keun Bon Ku

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28216367%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Chonsaeng Kim

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28216367%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Yun Young Go

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28216367%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Kai-Fa Huang

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28216367%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Meehyein Kim

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28216367%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Po-Huang Liang

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28216367%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

publication date

17 February 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28216367%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28216367%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

volume

141

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28216367%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

page(s)

101-106

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28216367%20AND%20SRC:MED&resulttype=core&format=json

Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection

3 April 2020

cites work

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro): IMPLICATIONS FOR nsp5 REGULATION AND THE DEVELOPMENT OF ANTIVIRALS.

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

Biosynthesis, Purification, and Substrate Specificity of Severe Acute Respiratory Syndrome Coronavirus 3C-like Proteinase

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

Structure-based design, synthesis, and evaluation of peptide-mimetic SARS 3CL protease inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

Cell-based antiviral screening against coronaviruses: developing virus-specific and broad-spectrum inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

Anti-SARS coronavirus agents: a patent review (2008 - present).

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

Critical Assessment of the Important Residues Involved in the Dimerization and Catalysis of MERS Coronavirus Main Protease

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

Viral replicase gene products suffice for coronavirus discontinuous transcription

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

Characterization of SARS main protease and inhibitor assay using a fluorogenic substrate

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

Mechanism of the maturation process of SARS-CoV 3CL protease

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

Broad-spectrum inhibitors against 3C-like proteases of feline coronaviruses and feline caliciviruses.

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: design, synthesis, biological evaluation, and docking studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

Peptide aldehyde inhibitors challenge the substrate specificity of the SARS-coronavirus main protease

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

Recent developments on coronavirus main protease/3C like protease inhibitors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

Structural Basis of Inhibition Specificities of 3C and 3C-like Proteases by Zinc-coordinating and Peptidomimetic Compounds

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacements

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

Susceptibility of inhibitors against 3C protease of coxsackievirus A16 and enterovirus A71 causing hand, foot and mouth disease: A molecular dynamics study

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

Evaluation of peptide-aldehyde inhibitors using R188I mutant of SARS 3CL protease as a proteolysis-resistant mutant

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

Structures of the Middle East respiratory syndrome coronavirus 3C-like protease reveal insights into substrate specificity

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

Mechanisms and enzymes involved in SARS coronavirus genome expression

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents.

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

Targeting zoonotic viruses: Structure-based inhibition of the 3C-like protease from bat coronavirus HKU4--The likely reservoir host to the human coronavirus that causes Middle East Respiratory Syndrome (MERS)

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

Design and synthesis of peptidomimetic severe acute respiratory syndrome chymotrypsin-like protease inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic alpha,beta-unsaturated esters

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

Characterization of a novel coronavirus associated with severe acute respiratory syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

Recent development of 3C and 3CL protease inhibitors for anti-coronavirus and anti-picornavirus drug discovery

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

Therapies for coronaviruses. Part 2: Inhibitors of intracellular life cycle.

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

CULTIVATION OF A NOVEL TYPE OF COMMON-COLD VIRUS IN ORGAN CULTURES.

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/28216367

12 December 2020

10.1016/J.ANTIVIRAL.2017.02.007

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28216367%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

PMC publication ID

7113684

0 references

1 reference